A Study of LY2140023 in Hepatic Impaired Participants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT01475136
First received: November 16, 2011
Last updated: January 10, 2013
Last verified: January 2013
  Purpose

This study will explore how liver impairment effects blood levels of LY2140023 (a prodrug) and its active metabolite LY404039.


Condition Intervention Phase
Hepatic Insufficiency
Drug: LY2140023
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: A Single Dose Pharmacokinetic Study of LY2140023 in Subjects With Hepatic Impairment

Further study details as provided by Eli Lilly and Company:

Primary Outcome Measures:
  • Pharmacokinetics: area under the concentration curve (AUC) of LY2140023 and LY404039 [ Time Frame: Pre-dose to 24 hours post-dose ] [ Designated as safety issue: No ]
  • Pharmacokinetics: maximum observed drug concentration (Cmax) of LY2140023 and LY404039 [ Time Frame: Pre-dose to 24 hours post-dose ] [ Designated as safety issue: No ]
  • Pharmacokinetics: time of maximal concentration (Tmax) of LY2140023 and LY404039 [ Time Frame: Pre-dose to 24 hours post-dose ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: November 2011
Study Completion Date: December 2012
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LY2140023
A single 80 mg dose administered orally, one time
Drug: LY2140023
Administered orally

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Male participants agree to use a reliable method of birth control during the study and for 3 months following the last dose of LY2140023
  • Female participants of child-bearing potential who test negative for pregnancy at screening and agree to use a reliable method of birth control for the duration of the study and for at least 3 months after the last dose of LY2140023
  • Female participants who are postmenopausal. Postmenopausal is defined as no menses for at least 1 year, or a plasma follicle stimulating hormone (FSH) value of greater than 40 IU/L, unless the participant is taking hormone replacement therapy
  • Have a body mass index (BMI) between 19 and 40 kg/m^2, inclusive at the time of screening
  • Have clinical laboratory test results within the normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator
  • Have sitting blood pressure and heart rate compatible with their disease state, as determined by the investigator
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
  • Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site
  • Control participants that have normal hepatic function, as determined by medical history and physical examination
  • Hepatically impaired participants that have stable hepatic impairment (for example, alcoholic, posthepatitis, biliary cirrhosis, cryptogenic) classified as Child-Pugh class A, B, or C (mild, moderate, or severe impairment) who are considered acceptable for participation in the study by the investigator

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued within the last 90 days from last dosing of an investigational product (other than the investigational product used in this study); or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to LY2140023, LY404039, or related compounds, or any components of the formulation
  • Have previously discontinued after receiving at least 1 dose of LY2140023 or completed this study or any other study investigating LY2140023 and or LY404039
  • Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption (except cholecystectomy), metabolism, or elimination of drugs; of constituting a risk when taking the study medication; or of interfering with the interpretation of data
  • Have evidence of significant active neuropsychiatric disease (for example, manic depressive illness, schizophrenia, depression)
  • Participants who answer 'yes' to either Question 4 (Active Suicidal Ideation with Some Intent to Act, Without Specific Plan) or Question 5 (Active Suicidal Ideation with Specific Plan and Intent) on the "Suicidal Ideation" portion of the C-SSRS, or answer "yes" to any of the suicide-related behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory act, or behavior) on the "Suicidal Behavior" portion of the Columbia Suicide Severity Rating Scale (C-SSRS); and the ideation or behavior occurred within the past 3 months
  • Have increased risk of seizures based on a history of:

    • One or more seizures (except for a single simple febrile seizure [lacking focality and lasting less than 15 minutes, not associated with a central nervous system (CNS) infection or severe metabolic disturbance] as a child between ages 6 months to 5 years)
    • Head trauma with loss of consciousness or a post-concussive syndrome within 1 year or lifetime history of head trauma with persistent neurological deficit (focal or diffuse)
    • CNS infection, uncontrolled migraine or transient ischemic attack (TIA) within 1 year; stroke with persistent neurological deficit (focal or diffuse), uncontrolled migraine is defined as migraine attacks that produce headache lasting up to 72 hours and are often accompanied by associated symptoms (nausea, photophobia, and phonophobia) that impair well-being and disrupt social functioning. TIA is defined as "mini-stroke" caused by temporary disturbance of blood supply to an area of the brain, which results in a sudden, brief decrease in brain function
    • CNS infection with persistent neurological deficit (focal or diffuse)
    • Brain surgery
    • Electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank seizures, spike-wave complexes, or sharp-slow wave complexes, or as locally defined)
    • Brain structural lesion, including developmental abnormalities, as determined by examination or imaging studies (does not include hydrocephalus unless treated by shunt or resulting in neurological deficits)
  • Known substance dependence unless approved prescription medication such as opiates, or known regular use of drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies
  • Women who are pregnant or intend to get pregnant during the study or within 3 months after the last dose of investigational product
  • Women who are breast feeding or lactating
  • Have donated blood of more than 500 mL within the last 3 months prior to the screening
  • Are organ transplant participants or have taken immunosuppressants following any organ transplant
  • Have shown signs of variceal bleeding during the last 2 months prior to screening (except for participants with severe hepatic impairment, detailed in exclusion criterion)
  • Show evidence of irritable bowel syndrome or chronic diarrhea
  • Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), and are participants unwilling to stop alcohol consumption for 96 hours predose until after 48 hours post-dose (1 unit equals 12 oz or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • Have a clinically significant abnormality in the neurological examination
  • Participants judged prior to dosing to be at suicidal risk by the investigator
  • Participants who are unwilling to refrain from smoking from midnight prior to dosing until 6 hours postdose or are unable to abide by the Clinical Research Unit (CRU) restrictions
  • Are on total parenteral nutrition (TPN)
  • Take oral anticoagulants for therapeutic use
  • Exhibit any other condition, which, in the opinion of the investigator would preclude participation in the study
  • Show evidence of pruritus or skin exfoliation
  • Have an eosinophil count >1.5 x 10^9/L
  • Have electrolyte imbalance alerts (clinically significant changes in calcium magnesium, or sodium)
  • Control Participants:

    • Have any medically significant history of neurologic disease, cancer, or cardiac, respiratory, metabolic, hepatic, renal, gastrointestinal (except appendectomy), dermatological, venereal, hematological disorder or disease
    • Have creatinine clearance (CrCl) less than 80 mL/min, as calculated by the Cockcroft-Gault equation Men: [(140 - age) x (weight in kg)] / [72 x (serum creatinine in mg/100 mL)] or [(140 - age) x (weight in kg)] / [0.81 x (serum creatinine in µmol/L)] Women in both of the above equations: (x 0.85)
    • Show evidence of significant active neuropsychiatric disease in the opinion of the investigator
    • Evidence of hepatitis B and/or positive hepatitis B surface antigen (HBsAg)
    • Show evidence of hepatitis C and/or positive hepatitis C antibody
    • Intend to use over-the-counter medication (including herbal remedies/health supplements) within 7 days prior to dosing, or prescription medication (other than hormone replacement therapy as described in inclusion criterion 1) within 14 days prior to dosing
  • Mild Hepatic Impaired Participants (Child-Pugh A):

    • show evidence of any significant active disease other than that responsible for or associated with hepatic impairment
    • have a platelet count of less than 50 x 10^9 cells/L unless after consultation with the Lilly Clinical Pharmacologist (CP), they are considered as acceptable for participation in the study
  • Moderate and Severe Hepatic Impaired Participants (Child-Pugh B and C):

    • Show evidence of any significant active disease other than that responsible for or associated with moderate or severe hepatic impairment
    • Have shown signs of spontaneous bacterial peritonitis within 6 months prior to dosing
    • Have severe hyponatremia
    • Show evidence of significant active neuropsychiatric disease
    • Have hepatic encephalopathy (Grades 2 to 4)
    • Have hemoglobin concentrations <9.0 g/dL
    • Show signs of hepatocellular carcinoma
    • Have a surgical portosystemic shunt
    • Have a platelet count of less than 40 x 10^9 cells/L (moderate impairment) or less than 30 x 10^9 cells/L (severe impairment), unless after consultation with the Lilly CP, they are considered as acceptable for participation in the study
    • Have shown signs of variceal bleeding during the last 2 weeks prior to screening (severe hepatic impaired participants only)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01475136

Locations
Germany
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Munich, Germany, 81241
Hungary
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Balatonfüred, Hungary, 8230
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
  More Information

No publications provided

Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT01475136     History of Changes
Other Study ID Numbers: 12677, H8Y-MC-HBCH, 2011-003033-34
Study First Received: November 16, 2011
Last Updated: January 10, 2013
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Hepatic Insufficiency
Liver Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on September 22, 2014